Holen Sie sich die Stockscreener-App
7.48
1.19%
-0.09
Vorhandelsmarkt:
7.43
-0.05
-0.67%
Schlusskurs vom Vortag:
$7.57
Offen:
$7.56
24-Stunden-Volumen:
262.82K
Relative Volume:
0.66
Marktkapitalisierung:
$380.56M
Einnahmen:
$228.37M
Nettoeinkommen (Verlust:
$31.11M
KGV:
12.25
EPS:
0.6108
Netto-Cashflow:
$41.73M
1W Leistung:
-0.40%
1M Leistung:
+26.78%
6M Leistung:
+36.00%
1J Leistung:
+152.70%
1-Tages-Spanne:
$7.44
$7.645
1-Wochen-Bereich:
$7.38
$7.8983
52-Wochen-Spanne:
$2.75
$7.8983
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
7.48 | 385.14M | 228.37M | 31.11M | 41.73M | 0.6108 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Eingeleitet | Goldman | Sell |
| 2018-05-11 | Bestätigt | Stifel | Buy |
| 2017-11-10 | Bestätigt | Citigroup | Buy |
| 2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Bestätigt | Stifel | Buy |
| 2017-09-11 | Bestätigt | Credit Suisse | Outperform |
| 2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Puma Biotechnology stock declines more than 9% in a month: Here's why - MSN
Ritholtz Wealth Management Boosts Stake in Puma Biotechnology - National Today
Puma Biotechnology, Inc. $PBYI Shares Acquired by Ritholtz Wealth Management - MarketBeat
What Do Analysts Think About Puma Biotechnology (PBYI)? - MSN
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Puma Biotechnology Stock Surges Past 200-Day Average - National Today
Puma Biotechnology (NASDAQ: PBYI) seeks votes to extend CEO warrant, elect directors - Stock Titan
Can Puma Biotechnology Inc sustain its profitabilityWeekly Stock Analysis & Real-Time Market Trend Scan - baoquankhu1.vn
PBYI PE Ratio & Valuation, Is PBYI Overvalued - Intellectia AI
Investor Mood: Is Puma Biotechnology Inc undervalued by DCF analysisWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 - BioSpace
Puma Biotechnology reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com
Pharma News: Is Puma Biotechnology Inc a momentum stockAnalyst Downgrade & Capital Efficiency Focused Ideas - baoquankhu1.vn
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
PBYI SEC FilingsPuma Biotechnology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Recap Report: What is Puma Biotechnology Incs 5 year growth outlook2026 Technicals & Low Risk Growth Stock Ideas - baoquankhu1.vn
Puma Biotechnology Q4 2025 slides: NERLYNX revenue rises 15% sequentially - Investing.com
Earnings call transcript: Puma Biotechnology Inc. reports strong Q4 2025 results - in.investing.com
Vanguard disaggregates holdings; Puma Biotechnology (PBYI) shows 0 shares reported - stocktitan.net
Forecast Cut: Is Puma Biotechnology Inc a momentum stockPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn
Rate Hike: Can Puma Biotechnology Inc be the next market leaderPortfolio Update Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Wall Street Zen Upgrades Puma Biotechnology (NASDAQ:PBYI) to Strong-Buy - MarketBeat
Shorts Report: Is Puma Biotechnology Inc undervalued by DCF analysis2026 Trading Volume Trends & Reliable Price Breakout Signals - baoquankhu1.vn
Whats the MACD signal for Puma Biotechnology Inc2026 Market WrapUp & Weekly Setup with ROI Potential - baoquankhu1.vn
Earnings Miss: Can Puma Biotechnology Inc be the next market leaderQuarterly Trade Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why - Yahoo Finance
Buy Signal: Is Puma Biotechnology Inc trading at a discount2026 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
Puma Biotechnology Stock Crosses 200-Day Moving Average - National Today
Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - TradingView
Published on: 2026-03-12 08:35:52 - baoquankhu1.vn
Puma Biotech (PBYI) Earnings Call Transcript - AOL.com
Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen - marketbeat.com
PBYI Q4 earnings & sales beat estimates, stock down on weak 2026 view - MSN
Puma Biotechnology, Inc. (PBYI) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Puma Biotech at TD Cowen Conference: Strategic Growth and Financial Discipline - Investing.com Canada
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2025 Earnings Call Transcript - Insider Monkey
PBYI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by Wall Street Zen - MarketBeat
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View - The Globe and Mail
PBYI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Puma Biotechnology Hits New 52-Week High of $7.68, Up 120% - Markets Mojo
Puma Biotechnology, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PBYI) 2026-02-27 - Seeking Alpha
Earnings call transcript: Puma Biotechnology Q4 2025 beats forecasts with strong revenue growth - Investing.com India
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Puma Biotechnology Q4 Earnings Call Highlights - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):